Journal of Pharmacovigilance

Evaluation of Amlodipine induced Pedal Edema (Eape) study

3^rd International Conference and Exhibition on Pharmacovigilance & Clinical Trials

October 27-29, 2014 Hyderabad International Convention Centre, India

Raman Garipelly

Posters: J Pharmacovigilance

Abstract:

Amlodipine is a dihydropyridine calcium channel blocker, used as antianginal and antihypertensive drug. Amlodipine has been successfully used as monotherapy in a large proportion of patients with mild-to-moderate hypertension. A prospective observational study was carried out at tertiary care hospital to evaluate amlodipine induced pedal edema. A total of 173 patients receiving amlodipine were enrolled into study and the overall incidence of pedal edema was found to be 28 (16.18%). The incidence of pedal edema was slightly higher among females than males, 17.39% and 15.38% respectively. The incidence of pedal edema was found to be dose-dependent, ranging from 8.33% for 5 mg and 26.58% for 10mg respectively. The incidence was higher in patients over 60-70 years (44.00%) followed by >70 years age group (35.29%). Post-menopausal women were found to be at higher risk to develop pedal edema, 9 (33.33%). Patients associated with chronic co-morbid conditions were found to be at increased risk to develop amlodipine induced pedal edema. As a remedy, drug was discontinued in 11 (39.28%) whereas dose tapering and drug addition was done in 8 (28.57%) patients. This study concludes that there is rise in the incidence of amlodipine induced pedal edema when compared to the previous data (10.8%). Older age, presence of co-morbidities and drug dose were found to be the risk factors for the development of pedal edema.

Biography :

Raman Garipelly is pursuing Doctor of Pharmacy (PharmD) at St. Peter?s Institute of Pharmaceutical Science affiliated to Kakatiya University. He has two research papers published in International journals. He has won best poster award at 4th IPASF (Indian Pharmaceutical Association - Students Forum) and best oral presentation award at National conference on Novel Targets of HIV therapy. He has been the former secretary of ISPOR (International Society for Pharmacoeconomics and Outcomes Research) - Student chapter. He has participated and volunteered in many conferences and presented posters at various events.